Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Linagliptin Inpatient Trial: A Randomized Controlled Trial on the Safety and Efficacy of Linagliptin (Tradjenta) Therapy for the Inpatient Management of General Surgery Patients With Type 2 Diabetes

Next Previous
Trial Profile

Linagliptin Inpatient Trial: A Randomized Controlled Trial on the Safety and Efficacy of Linagliptin (Tradjenta) Therapy for the Inpatient Management of General Surgery Patients With Type 2 Diabetes

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 07 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Linagliptin (Primary) ; Insulin; Insulin aspart; Insulin glargine; Insulin lispro
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Acronyms Linagliptin Surgery Trial

Most Recent Events

  • 05 Oct 2018 Results presented at the 54th Annual Meeting of the European Association for the Study of Diabetes
  • 13 Jun 2017 Results (n=251) presented at the 77th Annual Scientific Sessions of the American Diabetes Association
  • 08 Mar 2017 Status changed from recruiting to completed.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top